CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Canagliflozin and metformin hydrochloride

Last Updated: October 10, 2018
Result type: Reports
Project Number: SR0480-000
Product Line: Reimbursement Review

Generic Name: Canagliflozin and metformin hydrochloride

Brand Name: Invokamet

Manufacturer: Janssen Inc.

Therapeutic Area: diabetes mellitus, type 2

Indications: Diabetes mellitus, type 2

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: August 25, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions